 | Up a level |
Journal Article
Fischer, M., Wulff, B., Baruchel, S., Berlanga, P., Trahair, T., Mechinaud, F., Schulte, J., Modak, S., Merks, J. H., Zwaan, C. M., Marshall, L. V., Casanova, M., Branle, F., Malet, I., Emeremni, A. C. and Geoerger, B. (2016). Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population. Eur. J. Cancer, 69. S. S49 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Wolf, J., Schneider, C-P, Potzner, M., Arratia, Cazorla P., Shen, J., Branle, F. and von Pawel, J. (2015). The phase II ASCEND-7 (CLDK378A2205) trial: Ceritinib in patients (pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) metastatic to the brain and/or leptomeninges. Oncol. Res. Treat., 38. S. 138 - 139. BASEL: KARGER. ISSN 2296-5262